Physician profile
Michael Maidaa
NPI 1366008641
$13,636.75
in general payments reported to CMS, 2019-2025
24 companies · $7,850 in 2025
The $7,850 reported for 2025 was more than what 93% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2023: $4,180 · 2024: $1,505 · 2025: $7,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,520 · Education: $4,722 · Travel and Lodging: $2,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,520.17 |
| Education | $4,721.53 |
| Travel and Lodging | $2,293.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,571.84 | 2023-2025 | Ams 700, Rezum Generator, Lithovue |
| Intuitive Surgical, INC. | $4,500.00 | 2025 | |
| Coloplast Corp | $1,023.77 | 2023-2025 | Titan |
| Teleflex LLC | $745.87 | 2024-2025 | Barrigel, Urolift |
| Ambu INC. | $585.81 | 2024-2025 | |
| Astellas Pharma US INC | $582.63 | 2021-2025 | Xtandi |
| Procept Biorobotics Corporation | $499.81 | 2025 | |
| Urogen Pharma, INC. | $191.79 | 2025 | |
| Accord Healthcare, INC. | $140.16 | 2024-2025 | |
| Abbvie INC. | $137.53 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $128.73 | 2025 | Gemtesa, Orgovyx |
| Endo Pharmaceuticals INC. | $120.00 | 2023 | Xiaflex |
| Medtronic, INC. | $82.68 | 2025 | Interstim |
| Pfizer INC. | $46.55 | 2025 | |
| Janssen Biotech, INC. | $40.59 | 2025 | Erleada |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunitybio, INC. | $39.64 | 2024-2025 | |
| Endo USA, INC. | $38.94 | 2024-2025 | Xiaflex, Aveed |
| C. R. Bard, INC. & Subsidiaries | $30.96 | 2025 | Bard Urinary Drainage Bag |
| Myriad Genetic Laboratories, INC. | $28.79 | 2025 | Prolaris |
| Novartis Pharmaceuticals Corporation | $27.61 | 2025 | |
| Convatec INC. | $23.61 | 2025 | |
| Merck Sharp & Dohme LLC | $18.37 | 2024 | Keytruda, Welireg |
| Abc Home Medical Supply, INC. | $16.67 | 2025 | |
| Calyxo, INC. | $14.40 | 2025 | Cvac Aspiration System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Maidaa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.